Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007
Ghayas C. Issa(The University of Texas MD Anderson Cancer Center), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), James McCloskey(Hackensack University Medical Center), Marcie Riches(Medical College of Wisconsin), Amir T. Fathi(University of Southern California), Mohamad Khawandanah(University of Oklahoma Health Sciences Center), Gail J. Roboz(Cornell University), George Yaghmour(University of Tennessee Health Science Center), Hongling Zhang(Fujikura (United States)), James K. Mangan(UC San Diego Health System), Jessica K. Altman(Northwestern University), Stephen A. Strickland(Vanderbilt University), Tara L. Lin(Dana-Farber Cancer Institute), Daniel Corum(Fujikura (United States)), Gary J. Schiller(Fred Hutch Cancer Center), Mark Juckett(UW Health University Hospital), Keith W. Pratz(University of Pennsylvania), Ivana Gojo(Johns Hopkins University), Neil Palmisiano(Thomas Jefferson University Hospital), Harry P. Erba(Michigan Center for Translational Pathology), Amer M. Zeidan(Yale Cancer Center), Christine M. McMahon(Albert Einstein College of Medicine), Talha Badar(Mayo Clinic in Florida), Diaa Osman(Amway (United States)), Anjali S. Advani(Cleveland Clinic), Suresh Kumar Balasubramanian(Cleveland Clinic), Yazan F. Madanat(The University of Texas Southwestern Medical Center), Ying Tian, Mollie Leoni(Kura Oncology (United States)), Marcello Rotta(Colorado Blood Cancer Institute), Antoine N. Saliba(Mayo Clinic in Arizona)
Cited by 7
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k